Breast Cancer

Letrozole Is Superior Preoperative Therapy For Postmenopausal Women

Published in Cancer Weekly, December 11th, 2001

The largest preoperative aromatase inhibitor trial demonstrates that the breast cancer drug Femara (letrozole) is a more effective therapy for postmenopausal women with hormone receptor positive tumors than tamoxifen, the traditional gold standard treatment.

The data reveal that doctors can offer patients, who are not suitable for breast conserving surgery, an effective, tolerable, licensed therapy proven to shrink tumors. Breast conserving surgery after treatment with Femara may be a viable option in these patients, where previously a mastectomy would have been carried out.

Trialist, Professor Oleg Eremin, consultant breast surgeon at Lincoln...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry